Page 58 - NobleCon21

Health Care
Date November 20, 2025 Health Care
52wk High $0.03
52wk Low $0.01 Can-Fite BioPharma Ltd. CANF $0.01
26 Ben Gurion Street
Ramat Gan, N/A 5257346

(USD - in millions) www.canfite.com
Market Cap 51.2
Enterprise 29.8
Basic Shares Out. 5,121.87 COMPANY OVERVIEW
Float 4,699.36
Institutional Holdings 4.02% Detailed Analysis:Channelchek.com
Short Interest N/A
Avg. 90-Day Volume 1.22 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is
an advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion-dollar markets in the
treatment of cancer, liver, and inflammatory disease. The Company’s
EPS Data lead drug candidate, Piclidenoson reported topline results in a Phase III
trial for psoriasis and commenced a pivotal Phase III trial.
2022 2023 2024 Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III
CQ1 0.00 N/A 0.00 trial for hepatocellular carcinoma (HCC), a Phase IIb trial for the
CQ2 0.00 0.00 0.00 treatment of MASH, and in a Phase IIa study in pancreatic cancer.

CQ3 (0.03) 0.00 0.00
CQ4 0.00 (0.04) 0.00
CY (0.04) (0.04) 0.00 Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.00
ROE (ttm) -264.12
Debt-to-Total Cap. (mrq) 2.11
Fiscal Year End 31-Dec
26 Ben Gurion Ramat Gan N/A 5257346

Key Executives
CEO: Farbstein, Motti
CFO: Farbstein, Motti
COO: Farbstein, Motti
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures